Related Experiment Video
Updated: Apr 21, 2026

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Structural characterization and antitumor activity via immune modulation of an α-glucan from Grifola frondosa
Hui-Xiang Tian1, Qin-Zhao Ruan2, Yi-Zhen Xie3
1School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, China; National Health Commission Science and Technology Innovation Platform for Nutrition and Safety of Microbial Food, Guangdong Provincial Key Laboratory of Microbial Safety and Health, State Key Laboratory of Applied Microbiology Southern China, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou, 510070, China; Key Laboratory of Big Data Technologies for Food Microbiological Safety, State Administration for Market Regulation, NHC Specialty Laboratory of Food Safety Risk Assessment and Standard Development, Guangdong-Hong Kong-Macao Greater Bay Area Microbiological Safety and Health International Science and Technology Innovation Center, Guangzhou, 510070, China.
Abstract:
Grifola frondosa is a valued edible and medicinal fungus whose polysaccharides are key bioactive components, yet the identification of specific homogeneous effectors and their detailed immunomodulatory mechanisms remains a critical focus of research. In this study, polysaccharide fractions were isolated from G. frondosa fruiting bodies via systematic purification, and the principal bioactive polysaccharide responsible for breast cancer inhibition was identified. A novel homogeneous polysaccharide, GFI-21α, was determined as the primary effector. Structural characterization defined GFI-21α as a high-molecular-weight α-(1 → 4)-D-glucan backbone featuring →3,6)- and →4,6)-linked branch points substituted at the O-6 position with short →3)-α-D-Glcp-(1 → side chains. None of the isolated polysaccharide fractions exhibited direct cytotoxicity in vitro. However, in vivo experiments demonstrated that GFI-21α elicited substantial tumor growth suppression. This efficacy significantly exceeded that of the clinical β-glucan comparator, lentinan, without causing overt toxicity. Mechanistically, distinct from the innate immune modulation typically associated with β-glucans, GFI-21α was associated with enhanced intratumoral CD8+ T cell responses and IFN-γ-associated cytotoxic effector activity. These findings establish GFI-21α as a structurally distinct α-glucan with potent antitumor efficacy, supporting its potential as a candidate for cancer immunotherapy.

